Fwd: Scan Study Reveals No Association Between Statins And Cognitive Problems
Okechukwu Ogah
---------- Forwarded message ----------
From: ACC CV News Digest <ACCE...@acc.bulletinhealthcare.com>
Date: Tuesday, November 19, 2019
Subject: Scan Study Reveals No Association Between Statins And Cognitive Problems
To: osoga...@gmail.com
|
|||||
ACC in the NewsScan Study Reveals No Association Between Statins And Cognitive ProblemsThe New York Times (11/18, Bakalar) reports, “A large Australian study” encompassing 1,037 older adults and involving MRI brain scans “found no association between cholesterol-lowering statins and memory or thinking problems.” The study revealed that “the rate of cognitive decline was the same in those who used statins continuously and those who never took them.” In addition, “brain volume changes were the same in statin users and in those who never used the drugs.” ACC.org (11/18) reports that the researchers “examined changes in memory and global cognition regarding statin-use over a six-year observation period and two years of brain volume studies in 1,037 participants aged 70 to 90 years” and that “data were collected every two years on four occasions over the six-year period by psychologists and nurses.” The article says that “to measure the primary endpoints of memory and global cognition, the researchers developed a comprehensive assessment of global cognition and memory. Five memory tests were employed to assess new learning and short- and long-term recall using verbal and visual memory tasks.” Reuters (11/18, Carroll) reports that “the drugs” also “appeared to protect cognition in patients with heart disease,” the study found. The findings were published online in the Journal of the American College of Cardiology. To view the full JACC article, click here. Empirical POBI May Not Improve Rhythm Outcome Of Catheter Ablation Or Affect Type Of Recurrent Atrial Arrhythmia In Patients With AF, Research SuggestsCardiology Advisor (11/18) reports, “An empirical posterior box isolation (POBI) was not found to improve the rhythm outcome of catheter ablation or have an effect on the type of recurrent atrial arrhythmia in patients with atrial fibrillation (AF),” researchers concluded after evaluating “207 patients with persistent AF who underwent radiofrequency catheter ablation...for symptomatic and drug-refractory non-valvular AF and were randomly assigned to receive circumferential pulmonary vein isolation (CPVI) alone (n=105) or in combination with a complete POBI (n=102).” Participants were also “given a transthoracic echocardiography before undergoing RFCA, and received CPVI and cavotricuspid isthmus ablation.” The findings were published online in JACC: Clinical Electrophysiology. To view the full JACC: Clinical Electrophysiology article, click here. Two Studies Find Association Between Impella Pump And Increased Risk Of Death, Bleeding And Stroke In Patients Who Undergo AngioplastyHealthDay (11/18, Thompson) reports two separate studies presented at AHA 2019 indicate that the high-tech Impella pump “is associated with an increased risk of death, bleeding and stroke among patients undergoing angioplasty.” The research suggests that the expensive device used to maintain “blood flow during heart procedures could be more dangerous to patients than its low-tech predecessor.” Dr. Spencer King, a former president of the American College of Cardiology, said there should be more research to improve use of the device, “These kind of observations are very important to raise questions, to raise the hypothesis that we’re not using these things at the right time or in the right patients.” The article adds that one of the studies was also published in Circulation. Get full ACC coverage of AHA 2019 at ACC.org/AHA2019. RECOVERY Study Indicates That Patients With Asymptomatic Very Severe Aortic Stenosis Should Undergo Early Valve SurgeryMedPage Today (11/18, Susman) reports researchers concluded in the RECOVERY study that “patients who are diagnosed with asymptomatic very severe aortic stenosis should undergo early valve surgery rather than wait for symptoms to appear.” The researchers found that “in the primary endpoint of the RECOVERY (Randomized Comparison of Early Surgery vs Conventional Treatment in Very Severe Aortic Stenosis) study, a composite of operative mortality or death from cardiovascular causes in the four-year follow-up, one patient in the early-surgery group experienced the endpoint compared with 11 patients treated conservatively.” The findings were presented at the AHA 2019 and published in the New England Journal of Medicine. ACC.org (11/14) reports the researchers examined “145 asymptomatic patients with ‘very severe aortic stenosis’” with an average age of 64.2 years. The researchers randomly assigned the patients “to an early surgery group with aortic valve replacement within two months, or to conservative care according to the ACC/AHA guideline for the management of patients with valvular heart disease.” Get full ACC coverage of AHA 2019 at ACC.org/AHA2019.
Research Suggests Low LDL Cholesterol Target After Stroke Can Improve OutcomesMedPage Today (11/18, Phend) reports a study presented at AHA 2019 and published in the New England Journal of Medicine indicates that “for patients experiencing ischemic stroke or transient ischemic attack with evidence of atherosclerosis, setting a low LDL cholesterol target improved outcomes in the randomized Treat Stroke to Target trial.” The researchers found that “patients assigned to an LDL target of 70 mg/dL had a composite of ischemic stroke, myocardial infarction, new symptoms leading to urgent coronary or carotid revascularization, or death from cardiovascular causes at a rate of 8.5%, compared to 10.9% for patients randomized to a 90-110 mg/dL target.” ACC.org (11/18) reports the researchers examined “2,860 patients at 77 sites in France and South Korea who had an ischemic stroke in the previous three months or a TIA within the previous 15 days. All patients received statin with or without ezetimibe, and patients were randomly assigned to a low-target group with a target of LDL-C less than 70 mg per deciliter vs. a high-target group with a target of LCL-C from 90 mg to 110 mg per deciliter and were followed for a median of 3.5 years.” The researchers found “that the primary end point of a composite of major cardiovascular events – ischemic stroke, myocardial infarction, new symptoms leading to urgency coronary or carotid revascularization or death from cardiovascular cases – occurred in 121 patients in the low-target group vs. 156 in the high-target group. However, the investigators note that the trial was stopped early after 277 of 385 anticipated end-point events occurred.” MD Magazine (11/18, Campbell) reports the researchers “sought to determine the differences in relative risk when the target LDL-C is less than 70 mg/DL compared to 100 mg/dL.” Dr. Pierre Amarenco, the study’s lead investigator, said at the meeting, “This trial shows that after an ischemic stroke with evidence of target LDL cholesterol of less than 70 mg compared to 100 mg reduced the risk of subsequent cardiovascular events with no increase in intracranial hemorrhage and no increase in newly diagnosed diabetes.” Get full ACC coverage of AHA 2019 at ACC.org/AHA2019. Early Trial Results Indicate That Icosapent Ethyl Slows Development Of Artery-Clogging PlaquesHealthDay (11/18, Thompson) reports Dr. Matthew Budoff of UCLA’s David Geffen School of Medicine presented early results from the EVAPORATE trial testing Amarin’s Vascepa (icosapent ethyl) at AHA 2019. The article says the trial’s early results show that the drug, which is derived from fish oil, “slows the development of artery-clogging plaques.” The article adds that last week, “an FDA advisory panel unanimously voted in favor of expanded use of Vascepa.” ACC.org (11/18) also covers the EVAPORATE study. Get full ACC coverage of AHA 2019 at ACC.org/AHA2019. | |||||
|
|||||
Clinical News
GALILEO, GALILEO 4D Studies Suggest Mixed Results In Anticoagulation Post-TAVRMedscape (11/18, Busko, Kirkner, Subscription Publication) reports findings from “the first randomized prospective trial of an anticoagulation strategy vs standard dual antiplatelet therapy (DAPT) for patients undergoing transcatheter aortic valve replacement (TAVR) show that routine anticoagulation is not suitable for all comers in a high-risk population.” Specifically, “in the main GALILEO trial of elderly patients after TAVR, those who received an investigational anticoagulation strategy with the direct factor Xa inhibitor rivaroxaban (Xarelto, Bayer/Janssen) had worse survival and experienced more thromboembolic and bleeding events than patients who received standard DAPT.” But, “in the GALILEO 4D substudy of patients who underwent four-dimensional CT (4DCT), in which patients were randomly assigned to the two therapies, those in the rivaroxaban arm were less likely to show subclinical leaflet motion abnormalities and leaflet thickening.” The “full data analysis from GALILEO as well as the results from GALILEO 4D were” presented at AHA 2019 and published in the New England Journal of Medicine. Click here and here to read the studies. Get full ACC coverage of AHA 2019 at ACC.org/AHA2019. DTC Pediatric Telemedicine May Give Clinically Acceptable Results While Reducing Patients’ Need To Travel To Clinic, Researchers SayMedPage Today (11/18, Susman) reports, “Direct-to-consumer [DTC] pediatric telemedicine gave clinically acceptable results while saving patients and their families from making trips to the clinic that might have delayed treatment,” research indicated. Over the course of three years, “the telemedicine program was activated 39 times for cardiology-related pediatric ‘visits,’ and in a median follow-up of 187 days, no patients presented urgently to the hospital for a cardiology-related diagnosis after a direct-to-consumer visit, said Aaron Phillips, MD, of Children’s National Hospital in Washington, D.C., at” AHA 2019. Get full ACC coverage of AHA 2019 at ACC.org/AHA2019. Patients With History Of Kidney Stones More Likely To Have Adverse Outcomes After PCI, Study IndicatesRenal & Urology News (11/18, Charnow) reports a study published in Urology found that “patients who have a history of kidney stones are more likely to have adverse outcomes following percutaneous coronary intervention (PCI).” The study included data on “patients undergoing first-time PCI at Vanderbilt University Medical Center in Nashville, Tennessee, and the National Health Insurance Research Database in Taiwan” with cohorts of 11,289 and 155,762 patients respectively, “of whom 294 and 12,286 had a history of kidney stones.” TrendsExpert Says Promotion Of Cardiovascular Health Throughout Life May Lead To Healthier AgingMD Magazine (11/18, Walter) reports that “the best way to promote healthier aging might be by promoting better cardiovascular health throughout life,” according to a presentation at AHA 2019 given by Norrina Allen, PhD, and associate professor of preventive medicine and pediatrics at Northwestern University’s Feinberg School of Medicine. Allen “explained that along with reductions in mortality and cardiovascular disease, cardiovascular health is related to a wide range of important outcomes including quality of life, a reduction in depression, healthcare charges, and cognition.” Allen said that research has shown a connection between cardiovascular health and long-term outcomes, so it is important to start early to improve cardiovascular outcomes. Get full ACC coverage of AHA 2019 at ACC.org/AHA2019. Research News
Combination Of CT Angiography And Functional Tests Can Predict Likelihood Of Heart Attack And Death For At-Risk Individuals, Study FindsAunt Minnie (11/18, Kim) reports on a study published online November 18 in JAMA Cardiology finding that “the combination of coronary CT angiography scans and functional tests such as stress echocardiography can predict the likelihood of heart attack and death in individuals at risk of coronary artery disease based on their age.” Lead author Dr. Angela Lowenstern from the Duke University School of Medicine wrote, “Given the aging population, more older adults are presenting for evaluation of symptoms possibly related to CAD,” but, Lowenstern added, “identifying those who are at an increased risk for future cardiovascular events remains unclear.” Women With Diabetes Appear To Have A Five Times Higher Risk Of Heart Failure Than Women Without Diabetes, Research SuggestsHealthDay (11/18) reports, “Diabetes might be more deadly for women than men, at least when it comes to heart troubles,” research indicated. The study found that “women with diabetes have a five times higher risk of heart failure than women without diabetes, and men with diabetes have a two times higher risk than men without diabetes.” The findings were published online in the European Journal of Preventive Cardiology. Addition Of Bempedoic Acid To Statins May Reduce LDL Cholesterol In Patients At High Cardiovascular Risk, Study IndicatesCardiology Advisor (11/18, Ernst) reports researchers found in the phase 3 CLEAR Wisdom trial that “the addition of bempedoic acid to maximally-tolerated statins resulted in a significant lowering of low-density lipoprotein (LDL) cholesterol in patients at high cardiovascular risk.” The findings were published in JAMA Network Open. Industry NewsPacemaker Designed To Mimic Breath May Increase Blood Flow In Patients With Heart Failure, Rat Study SuggestsCardiovascular Business (11/18, Slachta) reports a study conducted in rats suggests that “a novel pacemaker designed to mimic a patient’s organic breath increased blood flow to the heart in a study of individuals with heart failure.” Erin L. O’Callaghan, the study’s first author, said, “We used state-of-the-art high-resolution echocardiography to monitor the heart’s performance during respiratory sinus arrhythmia pacing in rats with heart failure. Within two weeks there was a 20% increase in blood pumped by the heart, which was not the case when we used conventional pacemakers.” The findings were published in Thorax. Company Says Vericiguat Reduces Risk Of Heart Failure Hospitalization Or Cardiovascular Death In Patients With HFrEFReuters (11/18, Maddipatla, Nadeem) reports in a late-stage trial, the experimental drug vericiguat “reduced the risk of heart failure hospitalization or cardiovascular death in heart failure patients with reduced ejection fraction (HFrEF) when given in combination with available therapies” compared to placebo, according to Merck. The article says the drug was developed by Merck and Bayer “for patients with worsening chronic heart failure.” Merck also said that the results of the trial will be presented at a conference in 2020. Monday's Lead Stories • Gestational Preeclampsia, High Blood Pressure May Lead To Future Heart Problems, Study Suggests
• Withdrawal Of Aspirin From DAPT After Stenting For Non-ST-Segment Elevation ACS May Benefit High-Risk Patients, Research Indicates • Study Finds Association Between Maternal CV Health And Subsequent CV Health Of Child • Prognostic Value of Repeating CMR in Patients With Acute Myocarditis |
|||||
|
Advertise with BulletinHealthcare: Reach key professionals every morning
 |
|||||
|
CV News Digest is a daily news briefing selected from thousands of sources by the editors of BulletinHealthcare. The mission of CV News Digest is to alert members of the American College of Cardiology about cardiovascular-related information that their patients may read or hear in the media that day. Opinions expressed in CV News Digest are those of the identified authors and do not necessarily reflect the opinions or policies of the ACC. On occasion, media articles may include or imply incorrect information about the ACC and its policies, positions, or relationships. For clarification on ACC positions and policies, we refer you to ACC.org. The presence of advertising does not endorse, or imply endorsement of, any products or services by the ACC. This complimentary copy of the CV News Digest was sent to osoga...@gmail.com as part of your ACC membership. To see how we protect our data, or for any questions on data access, view BulletinHealthcare's privacy policy.
To prevent mailbox filters from deleting your CV News Digest, add ACCEditor@acc.bulletinhealthcare.com to your address book. American College of Cardiology | Heart House | 2400 N Street, NW | Washington, DC 20037 Copyright © 2019 by BulletinHealthcare | 11190 Sunrise Valley Drive, Suite 20 | Reston, VA 20191 |
&cid=&e=&c=2019111901acc&pubid=107&siteid=10717&p=1)
&cid=&e=&c=2019111901acc&pubid=107&siteid=10717&p=2)
--
Consultant Cardiologist,
Division of Cardiology
Department of Medicine,
University College Hospital Ibadan
PMB 5116, Ibadan, Oyo State, NIGERIA
Tel. +234 806 77 47 121
Fax. +1215-975-6817 (Electronic)
Email: osoga...@yahoo.com OR osoga...@gmail.com
"For with thee is the fountain of life: in thy light shall we see light." Psalm 36:9
-------------------------------------------------------------------------------------------------
Basil Okeahialam
To prevent mailbox filters from deleting your CV News Digest, add ACCEditor@acc. bulletinhealthcare.com to your address book. |
|
American College of Cardiology | Heart House | 2400 N Street, NW | Washington, DC 20037 Copyright © 2019 by BulletinHealthcare | 11190 Sunrise Valley Drive, Suite 20 | Reston, VA 20191 |
--
Consultant Cardiologist,
Division of Cardiology
Department of Medicine,
University College Hospital Ibadan
PMB 5116, Ibadan, Oyo State, NIGERIA
Tel. +234 806 77 47 121
Fax. +1215-975-6817 (Electronic)
Email: osoga...@yahoo.com OR osoga...@gmail.com
"For with thee is the fountain of life: in thy light shall we see light." Psalm 36:9
-------------------------------------------------------------------------------------------------
You received this message because you are subscribed to the Google Groups "NIGERIAN CARDIAC SOCIETY" group.
To unsubscribe from this group and stop receiving emails from it, send an email to nigerian-cardiac-s...@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/nigerian-cardiac-society/CAEseqwO-sutoESU7dCEn3y5%2BG%3DKCESjD%2Bdyjeh-ee7Ty%3Di4N%2Bg%40mail.gmail.com.